RxDoctor Payments Data

Cory Amador, PA

Medical · San Bernardino, CANPI 1801082946

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $21,477 of the $30,768 with a category attached, or 69.8%. Gilead accounts for 98.2% of it on its own, with 5 other manufacturers making up the rest. Among medical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$30,768in general payments, 2019–2025

Across 119 payments — averaging $258.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$30K
  • AbbVie$402
  • Boston Scientific$60
  • Integra Lifesciences Corporation$37
  • Mallinckrodt Hospital Products Inc.$24
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$16

What the payments were for

  • Consulting fees$2,0407%
  • Speaking & faculty fees$21,47770%
  • Travel & lodging$4,86516%
  • Food & beverage$2,3868%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,768 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$40,108
Medicare patients
133
Services billed
425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin35$115,578
LokelmaSodium Zirconium Cyclosilicate86$88,824
VeltassaPatiromer Calcium Sorbitex27$27,704
VemlidyTenofovir Alafenamide15$21,220
Tacrolimus118$15,188
Entecavir17$6,032
Valganciclovir Hcl45$3,746
Ursodiol20$2,478
Humalog Kwikpen U-100Insulin Lispro13$1,945
Insulin Lispro Kwikpen U-100Insulin Lispro11$1,686
Mycophenolate Mofetil24$1,325
Fluconazole24$455
Spironolactone11$334
Tamsulosin Hcl44$280
Pantoprazole Sodium49$266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$16$115,57835 claims
GileadVemlidy$30,229$21,22015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.

Other medical in San Bernardino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →